December 13, 2017 7:50am
But sentiment is like a flu that keeps infecting the sector
We need am antibiotic
Pre-open indications: 5 BUYs and 2 SELL
Financing: bluebird bio (BLUE) Prices 3.343 M share offering at $185.00 - https://www.regmedinvestors.com/articles/10040
Can’t read because of no subscription rights - you’re missing situational awareness and the most trustworthy source of independent insight!
Flat open expected
Dow futures are UP +0.04% (+11 points) and NASDAQ futures are UP +0.05% (+3.5 points)
U.S. stock index futures are set for a flat to lower open on Wednesday as a monetary policy decision from the Federal Reserve looms.
Asian markets closed mostly higher as the dollar edged down following a projected Democrat win in Alabama. Investors also awaited the conclusion of the Federal Reserve's two-day policy meeting.
Asian markets closed mostly higher as the dollar edged down following a projected Democrat win in Alabama. Investors also awaited the conclusion of the Federal Reserve's two-day policy meeting.
Issues that will affect the trading day: While politics and individual stock news may move markets somewhat during today's session, investors will be placing most of their attention on a rate decision and policy announcements by the U.S. Federal Reserve, all due out at 2 p.m. ET.
Data docket: Consumer price index (CPI) figures are also set to be released at 8:30 a.m. ET.
Issues on the political front: Aside from an interest rate decision, traders will be paying close attention to what the Fed will say in regards to tax reform and the state of the U.S. economy.
Henry’omics:
From Tuesday night’s closing bell post, “…sentiment is more than a threat as I had stated, “ASH giveth and taketh … away”. The sector dumped, the NASDAQ falls as bluebird bio (BLUE) proposes offering planning to sell $600 million worth of shares, with the possibility of increasing the size by up to 15%. BLUE is down -$10.85 or -5.38% to $190.975 as VistaGen (VTGN), Capricor (CAPR) and Fibrocell (FCSC) and the newest offering proposal, FATE continue to show the need. Dependence on capital market funding is still a prop that drives investor’s negative vibes.”
We - the sector needa a catalyst, a kick or an antibiotics to cure the hangover left from sentiment - that also continues to linger ...
But, it just isn't being oversold that will find buyers !
The RegMed and cell therapy sector closed NEGATIVE on Tuesday and Monday, NEUTRAL on Friday, POSITIVE on Thursday and NEGATIVE last Wednesday.
The cell therapy sector’s record over 5 sessions (of 40 covered companies):
· Tuesday closed NEGATIVE with 27 decliners, 11 advancers and 2 flats;
· Monday closed NEGATIVE with 27 decliners, 12 advancers and 1 flat;
· Friday closed NEUTRAL with 19 decliners, 19 advancers and 2 flats;
· Thursday closed POSITIVE with 11 decliners, 24 advancers and 5 flats;
· Last Wednesday closed NEGATIVE with 29 decliners, 7 advancers and 4 flats
You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what are today’s indications?
Watch list:
- The iShares Nasdaq Biotechnology (IBB) is NOT indicating in Wednesday’s pre-market;
- The SPDR S&P Biotech ETF (XBI) is NOT indicating in Wednesday’s pre-market;
- The Health Care Select Sector SPDR ETF (XLV) is NOT indicating in Wednesday’s pre-open;
- The iShares Russell 2000 (IWM) is indicating a NEGATIVE -0.05% in Wednesday’s pre-open
Companies in my headlights:
Bellicum Pharmaceuticals (BLCM) closed down -$0.65 to $8.51 after Monday’s -$0.37 to $9.16 after Friday’s +$0.32 to $9.53 with 329.5 K shares traded <3 month average =454.3 K shares>. The aftermarket indication is a negative -$0.10 or -1.18% – BUY to SELL;
bluebird bio (BLUE) closed down -$10.85 to $190.95 after Monday’s -$30.95 to $ +$30.65 to $201.80 with 5.12 M shares traded after Friday’s +$3.25 to $171.15 with 727.2 K shares traded <3 month average = 777.4 K shares>. BLUE priced its 3.343 M share offering at $185.00 - BUY;
BioLife Solutions (BLFS) closed down -$0.13 to $5.44 with 30.2 K shares traded, <3 month average = 180.9 K shares> Rack-up another client signing as Iovance Biotherapeutics joins the band, new is always a catalyst for BLFS – BUY;
Fate Therapeutics (FATE) closed up +$0.295 to $4.435 after Monday’s -$0.03 to $4.14 and Friday’s -$0.02 to $4.17 which jumped +$0.28 or +6.71% to $4.45 after closing on news of the first subject has been treated in the APOLLO study of FATE-NK100 in women with ovarian cancer. Fate on Monday announced today that IND-enabling production of FT500 has commenced at University of Minnesota, Molecular and Cellular Therapeutics, a state-of-the-art, FDA-registered Good Manufacturing Practice (GMP) facility. The aftermarket indication is a negative -$0.22 or -5.07%. On the back of news and its upside, FATE announced an offering - BUY to SELL;
Juno Therapeutics (JUNO) closed down -$4.49 to $45.75 with 7.31 M shares traded after Monday’s -$8.41 to $50.24 after Friday’s +$1.92 to $58.65 with 2.37 M shares traded <3 month average = 2.28 M shares> after Thursday’s +$2.17 to $56.73 with 1.18 M shares traded after Wednesday’s +$1.36 to $54.56 after last Tuesday’s -$1.46 to $53.20 with 1.45 M shares trading. November started at $78.56 had a high of $82.06 and a low of $68.25 on 11/14 while October ended at $80.90 having started at $89.37. The aftermarket indication is a POSITIVE +$0.23 or +0.5% – Maintaining BUY;
MiMedx Group (MDXG) closed up +$0.60 to $12.25 with 1702 shares traded <3 month average = 2.832 M shares>. MDXG issued guidance for 2018 forecasting 2018 revenue to be in the range of $383 Million to $387 Million and gross profit margins expected to be in the range of 89% to 90%. The aftermarket indication is a positive +$0.15 or +1.22% - BUY;
Regenxbio (RGNX) closed down -$2.25 to $27.15 with 407.5 K shares traded after Monday’s -$2.25 to $29.50 after Friday’s +$1.45 to $31.75 with 325.7 K shares traded <3 month average = 368.1 K shares> after Thursday’s +$0.85 to $30.30 with 391.8 K shares traded after Wednesday’s +$1.25 to $29.45 with 198.9 k shares traded <3 month average = 362.9 K shares>. December started out at $28.90 following Novembers end at $28.10 and start at $28.00 with a low of $26.00 and a high of $29.70. On Thursday, The aftermarket indication is a positive +$0.95 or +3.22%–Maintaining BUY;
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
